Pixuvri (pixantrone dimaleate)
- Region
- 🇪🇺 EU
- Active substance
- pixantrone dimaleate
- Company
- Les Laboratoires Servier
- Status
- Expired
- Therapeutic area
- Lymphoma, Non-Hodgkin
- CHMP opinion
- Thu 16 Feb 2012
- EU approval
- Thu 10 May 2012
- Application
- EMEA/H/C/002055
- ATC
- L01DB11
- Official record
- www.ema.europa.eu
Indication
Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Pixuvri
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.